Old Web
English
Sign In
Acemap
>
authorDetail
>
C L Kannowski
C L Kannowski
Eli Lilly and Company
Rheumatoid arthritis
Physical therapy
Baricitinib
Medicine
Visual analogue scale
2
Papers
9
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison
2020
RMD Open
Bruno Fautrel
B Zhu
Peter C. Taylor
M.A.F.J. van de Laar
Paul Emery
F. De Leonardis
C L Kannowski
Claudia Nicolay
Z. Kadziola
I. de la Torre
Roy Fleischmann
Show All
Source
Cite
Save
Citations (8)
FRI0048 NUMBER NEEDED TO TREAT TO ACHIEVE MINIMUM CLINICALLY SIGNIFICANT DIFFERENCES IN PATIENT-REPORTED OUTCOMES IN PATIENTS TREATED WITH BARICITINIB
2020
Annals of the Rheumatic Diseases
Vibeke Strand
L. Sun
J. Ross Terres
C L Kannowski
Show All
Source
Cite
Save
Citations (1)
1